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Venomous animals immobilize prey using protein toxins that act
on ion channels and other targets of biological importance. Broad
use of toxins for biomedical research, diagnosis, and therapy has
been limited by inadequate target discrimination, for example,
among ion channel subtypes. Here, a synthetic toxin is produced by
a new strategy to be specific for human Kv1.3 channels, critical
regulators of immune T cells. A phage display library of 11,200 de
novo proteins is designed using the -KTx scaffold of 31 scorpion
toxin sequences known or predicted to bind to potassium chan-
nels. Mokatoxin-1 (moka1) is isolated by affinity selection on
purified target. Moka1 blocks Kv1.3 at nanomolar levels that do
not inhibit Kv1.1, Kv1.2, or KCa1.1. As a result, moka1 suppresses
CD3/28-induced cytokine secretion by T cellswithout cross-reactive
gastrointestinal hyperactivity. The 3D structure of moka1 rational-
izes its specificity and validates the engineering approach, reveal-
ing a unique interaction surface supported on an -KTx scaffold.
This scaffold-based/target-biased strategy overcomesmany obsta-
cles to production of selective toxins.
mokatoxin  moka1  phage display  peptide toxin  animal venom
The voltage-gated potassium channel expressed on human Tlymphocytes, Kv1.3, is a validated target for therapeutic
modulation of the immune system (1–3). Thus, block of Kv1.3 on
T cells by scorpion toxins counters the effects of anti-CD3/28
stimulation and suppresses effector cytokine secretion. This
observation has motivated efforts to isolate native toxins specific
for Kv1.3 from venoms and to design peptide and small molecule
blockers (4–8). Regrettably, these natural and synthetic ligands
have proven inadequate. For example, kaliotoxin-1 (KTX) (9)
inhibits Kv1.3 to suppress T cell activity (10) but also blocks
Kv1.1 and Kv1.2 (11) with sufficient potency to produce unde-
sirable side effects such as diarrhea (12). Efforts to improve
selectivity continue (2, 3, 13, 14).
The search for target-specific toxins is fueled by their proven
utility and physical stability. Progress has been slow with current
sources of new toxins—isolation from crude venom, shotgun
venom gland sequencing, and site-directed mutation. This is
because minute amounts of toxins are present in venoms,
isolation is rarely coupled to known targets, effective strategies
are lacking to link peptides predicted by sequencing or generated
by combinatorial chemistry with targets of interest, and variation
explored by point mutation is limited (15).
Here, we circumvent these obstacles by production of a
scaffold-based/target-biased library and a high-throughput se-
lection strategy. The library was constructed on the resilient
scaffold found in scorpion -KTx toxins (16, 17). This seemed
prudent first because animal toxin scaffolds have evolved to
tolerate extensive sequence diversity (18), and second because
-KTx toxins interact with potassium channels. Phage display
and library sorting (19) were judged practical because proper
folding of disulfide-rich proteins has been observed on phage
(20), toxins remain active despite non-native residue variation (2,
6, 21, 22), and phage displaying random peptides have been
sorted on ion channels (23). Design, isolation, and characteriza-
tion of mokatoxin-1 (moka1), an avid and specific blocker of
human Kv1.3 channels are described.
Results
Phage Display of a Neurotoxin. Seeking a toxin specific for Kv1.3
we chose KTX, a scorpion venom peptide with an -KTx scaffold
that blocks Kv1.3 channels by a well-defined mechanism, as the
lead for library design. -KTx toxins bind directly in the potas-
sium ion conduction pore to occlude the pathway (16) with
affinities that are exquisitely sensitive to residues on the toxin
and channel interaction surfaces (21, 24, 25). It follows that
specific binding of phage to achieve library sorting demands that
toxin variants (i) are synthesized and fold correctly (after
proteolytic cleavage of the leader sequence that mediates surface
expression), (ii) are accessible to target from the phage surface,
and (iii) bind target in a stable manner despite their phage cargo.
To establish that phage could display KTX and bind to Kv1.3,
nucleotides encoding the toxin were inserted upstream and
in-frame with the gene for phage coat protein III (26). As a
control, phage expressing a mutant KTX (DDD-KTX) that does
not bind to Kv1.3 were also produced. DDD-KTX has three
negatively charged Asp residues at sites where KTX has basic
residues critical for binding: Arg24, Arg31, and Lys27—the last a
conserved residue in -KTx toxins with an -amino group that
penetrates the ion conduction pore (16).
As a selection target, tetrameric channel complexes were
synthesized bearing the pore-forming (P) domain from human
Kv1.3 grafted into the homologous location of the bacterial
potassium channel KcsA (to create KcsA-1.3), a strategy devel-
oped by others to study interaction of KTX and purified channel
complexes (27). Wild-type KcsA channels were produced to test
for nonspecific binding.
Phage expressing KTX were shown by ELISA to bind to
immobilized KcsA-1.3 channels in a stable and specific manner
because they were not recovered on wild-type KcsA (Fig. 1A).
Binding was shown to require expression of wild-type toxin
because neither KcsA-1.3 nor KcsA channels retained DDD-
KTX phage. Specific binding of KTX phage to KcsA-1.3 chan-
nels argued that selective sorting of a toxin library was feasible.
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A Neurotoxin Library Yields Mokatoxin-1. A combinatorial library
was designed based on the sequences of 31 known or predicted
-KTx toxins (Table S1). To preserve scaffold architecture and
favor folding of de novo toxins, the number and relative positions
of disulfide bridges were preserved; further, two conserved
regions corresponding to KTX residues Gln13Cys14 (QC) and
Lys27Cys28Met29 (KCM) were maintained or introduced (Fig.
1B). Thus, toxin sequences were aligned at the six conserved Cys
residues that form three disulfide bonds by allowance for inser-
tions and deletions, and the QC and KCM regions were used to
define three domains (A, B, and C) in all toxin sequences (Fig.
1B). The 31 parent toxins contain 30, 22, and 17 unique A, B, and
C domains, respectively. Genes were produced by ligation of
oligonucleotides for the domains using QC and KCM residues as
shared linkers (Table S2). DNA sequencing showed incorpora-
tion of all domains in the library. Restricted permutation to form
all toxins with the ABC pattern yields a calculated diversity of
11,200 unique toxins and reconstitution of 20 parental toxins.
Multiple independent phage expressing moka1 were isolated
after two rounds of library selection using KcsA-1.3 as the target
(Table S3). Moka1 was not observed in trials with wild-type
KcsA as target. To confirm that isolation of moka1 was a specific
process, phage expressing moka1 were diluted with those dis-
playing DDD-KTX at a ratio of 1:15,000 to approximate their
frequency in the library. After two rounds of selection on
KcsA-1.3, 40% of phage carried moka1. Conversely, no enrich-
ment was observed on wild-type KcsA where all recovered phage
hadDDD-KTX. Enrichment of moka1 phage in trials of this type
was 75 to 350-fold per cycle (Tables S4–S6).
The A, B, and C domains in moka1 are derived from three
scorpion species (Fig. 1B). Domain A is from toxin Ce3 of the
Central American Centruroides elegans (5). Domain B is in
agitoxin-2 (AgTx2) and agitoxin-3 (AgTx3) of theMiddle Eastern
Leiurus quinquestriatus (28) and kaliotoxin-3 (KTX3) of the
North African Buthus occitanus (29). Domain C is in charybdo-
toxin (CTX) and Lq2 of the Middle Eastern L. quinquestriatus
(30). Moka1 maintains the basic character of -KTx toxins with
four predicted net-positive charges at neutral pH.
Structure and Pharmacology of Mokatoxin-1. The solution structure
of moka1 was determined by NMR spectroscopy (Fig. 2A and
Table S7). The overall structure shows the peptide to preserve
the -KTx scaffold. Moka1 is more closely related to AgTx2 and
CTX (Fig. 2B Left) than to KTX (Fig. 2B Right), althoughmoka1
and KTX share a short and distorted helical region due to Pro
at homologous sites (positions 14 and 17, respectively) (31).
These structural features are consistent with the tripartite nature
of moka1 (Fig. 2C).
Moka1 was synthesized by solid-phase peptide synthesis, and
the free product (without accompanying phage) found to block
human Kv1.3 channels potently and selectively. Application of 1
nM moka1 suppressed half the current of channels expressed in
Xenopus oocytes in reversible fashion (Fig. 3A), showing a rapid
on-rate (39  106  6  106/Ms) and slow off-rate (0.056 
0.006/s) as expected for a high-affinity interaction (Fig. 3B and
Tables S8 and S9).
Importantly, the pharmacological profile of moka1 was unlike
any of its three parental toxins or KTX. Though moka1 blocked
Kv1.3 in the nanomolar range, it was over 1,000-fold less potent
on Kv1.1 (17% inhibition at 1M), 620-fold less potent on Kv1.2,
and had no measurable effect on KCa1.1 at 1 M (Fig. 3C).
Conversely, nanomolar affinity was observed for AgTx2 with
Kv1.1, Kv1.2, and Kv1.3, for CTXwith Kv1.2, Kv1.3, and KCa1.1,
and Ce3 is reported to be a low-affinity blocker of Kv1.3 with a
Ki of 366 nM (5). While the library template toxin KTX binds
Kv1.3 with high affinity and effectively differentiates Kv1.3 and
Kv1.2, it is less able thanmoka1 to distinguish between Kv1.3 and
Kv1.1 (Fig. 3D).
While the unique pharmacology of moka1 could not have
been anticipated based on the traits of its three parent toxins, it
can be rationalized by its unique 3D structure. Five residues that
populate the majority of the channel-binding surface around the
Fig. 1. KcsA-1.3 channels bind KTX phage and isolate moka1 phage from an -KTx scaffold library. Phage preparation, library construction, sorting and ELISA
protocols, and KcsA, KcsA-1.3, and toxin synthesis and purification are described in SI Materials and Methods. Single-letter codes for amino acids are standard
with Z for pyroglutamate. (A) ELISA shows KTX phage bind to KcsA-1.3 but not wild-type KcsA channels (Left) and phage expressing KTX bind to KcsA-1.3
channels, whereas those expressing DDD-KTX do not (Right). Ninety-six well plates coated with KcsA-1.3 or KcsA were incubated with phage (108–1010/well). Data
are mean SE. for three wells. (B) Library construction and sorting. Thirty-one scorpion toxins that share the-KTx scaffold were aligned to define three domains
(A, B, and C). In KTX, domains were from residues Gly1-Pro12 (A), Leu15-Gly26 (B), and Asn30-Lys38 (C). Domains were linked by sharing of nucleotide codes for amino
acids QC (A and B) or KCM (B and C), thereby conserving the important KTX residue Lys27. This yields 30, 22, and 17 unique A, B, and C domains, respectively,
and a calculated library diversity of 11,220. Moka1 (GQ153941), a unique toxin isolated from the library, is composed of residues present in the natural toxins
Ce3 (red), AgTx2 (yellow), and CTX (blue). Mo´ka is a Hungarian word that translates into English as fun. Isolation of two or more identical clones in 20 by sorting
was the basis for further study because the probability of this in the absence of enrichment (e.g., randomly) is smaller than 108.
22212  www.pnas.orgcgidoi10.1073pnas.0910123106 Takacs et al.
canonical pore-directed -KTx Lys are from Ce3 (Leu7 and
Pro8), AgTx2 (Phe22), and CTX (Arg31 and Tyr33) (Fig. 2C), an
array of residues not seen in natural -KTx toxins. Further, the
N terminus in -KTx toxins can modify toxin binding (21, 25, 32,
33), and the segment in moka1 is shorter and altered in position
compared with AgTx2, CTX, and KTX (Fig. 2B).
Mokatoxin-1 Acts on T cells but Not the GI tract.Human T cells were
used to confirm that moka1 was active on Kv1.3 channels in their
natural milieu. Consistent with expectations, moka1 inhibited
secretion of TNF-, IL-2, and IFN- at concentrations as low as
1 nM when CD3 T cells were stimulated with anti-CD3/28
beads (Fig. 4A). Moreover, there was no reduction in cell
viability with 1 M moka1, indicating that suppression was not
due to cytotoxicity and that toxin exposure was tolerated even at
high concentrations. That moka1 inhibits T cells more potently
than KTX (Fig. 4A) despite a lower affinity for human Kv1.3
channels expressed in oocytes (Fig. 3D) highlights the impor-
tance of native receptor milieu.
To confirm that moka1 did not cross-react with native gas-
trointestinal Kv channels, isolated ileal segments were studied
(Fig. 4B). Whereas native -KTx toxins have been shown to
increase twitch frequency and lower the pressure threshold for
eliciting peristaltic contractions (12), moka1 from 1 to 100 nM
neither led to twitching nor altered the pressure threshold for
contraction. In contrast, KTX at just 10 nM induced both effects
significantly. These effects of KTX are caused by inhibition of
Kv1.1 channels and abolished by tetrodotoxin, consistent with
mediation via the enteric nervous system (34).
Discussion
Sushruta Samhita, a text in Vedic Sanskrit attributed to Sushruta
(sixth-century BC) describes whole venoms as curatives. More
recently, native, recombinant, and chemically modified peptide
toxins and small molecule mimics have served as leads for drug
development or found use in medical therapy, for example, as
anticoagulants and in pain management (35). Here, a de novo
toxin is made for the immunotherapeutic target Kv1.3 using a
scorpion neurotoxin scaffold. Supporting its potential efficacy,
moka1 exhibits a desirable profile that differs from other toxins
and small molecules and inhibits human T cell cytokine release
via Kv1.3 without increasing gastrointestinal motility due to
cross-reaction with Kv1.1.
The attributes of moka1 validate scaffold-based/target-biased
library design as a strategy to exploit the evolution-tested
robustness of animal toxin scaffolds and their known associa-
tions with target classes. Combined with the power of phage
display, the approach overcomes major obstacles to isolation of
target-specific toxins. Thus, new toxins are isolated based on
interaction with the target and are physically linked to their
Fig. 2. Structure of moka1. Production of [U-13C, 15N]-moka1 and NMR
spectroscopy are described in SI Materials and Methods. Statistics of the final
structures are in Table S7 (A) Moka1 retains the -KTx fold. NMR-derived
solution structure of moka1 (PDB ID code 2kir). The C traces (gray) of 20
structures of moka1 are superimposed. The Cys residue side chains and the
disulfide bonds are shown in yellow. (B Left) Superposition of the structure of
moka1 (gray) with CTX (blue; PDB ID code 2crd) and AgTx2 (yellow, PDB ID
code 1agt). (Right) Superposition of the structure of KTX (purple; PDB ID code
1ktx) and moka1 (gray). (C) The moka1 surface that is predicted to interact
with the channel is shown en face in stick (Left) and surface representations
(Right). Portions of moka1 originating from parental toxins are marked with
different colors: Ce3 (red), AgTx2 (yellow), and CTX (blue). Residues common
to all (QC and KCM) are shown in gray. Moka1 Lys24 equivalent to KTX Lys27
that is inserted in the channel pore is marked by an asterisk (*).
Fig. 3. Moka1, a high-affinity and specific Kv1.3
channel blocker. Ion channel isoforms expressed in
Xenopus laevis oocytes and studied by two electrode
voltage clamp included rat Kv1.1, rat Kv1.2, human
Kv1.3, and mouse KCa1.1. Bath solution was (in mM): 2
KCl, 96 NaCl, 1 MgCl2, 1.8 CaCl2, 5 Hepes (pH 7.5), and
0.1% bovine serum albumin (BSA). Equilibrium inhibi-
tion was determined by fitting dose-response curves
for moka1 and calculated for other toxins from percent
block. kon and koff were calculated. Methods are de-
scribed in depth in SI Materials and Methods. (A)
Representative current traces for human Kv1.3 chan-
nels before, in the presence of, and after washout of 3
nM moka1 at steady state. (Scale bars: 2 A and 200
ms.) Voltage protocol: holding voltage 100 mV, 500
ms steps of 15 mV from60 mV to 30 mV followed by
a 200 ms step to135 mV with a 30-s interpulse inter-
val. (B) The time course for block and unblock of hu-
man Kv1.3 on acute application (bar) and washout of 3
nM moka1 during 100 ms steps to 0 mV from100 mV followed by a 200-ms step to135 mV every 2 s. (Inset) Voltage protocol. (C) Dose-response relationships
for moka1 inhibition of human Kv1.3 (F), rat Kv1.1 (Œ), rat Kv1.2 (}), and mouse KCa1.1 (■), n 3–11 cells. Kv1.1, Kv1.2, or Kv1.3 peak currents were recorded
during a 500-ms step every 30 s to 0 mV from a holding voltage of100 mV, followed by a 200-ms step to135 mV. KCa1.1 currents were recorded with 50-ms
steps every 3 s to 60 mV from 80 mV, followed by a 40-ms step to 100 mV. (D) Measured equilibrium inhibition (nM) for moka1, KTX, AgTx2, CTX on Kv1.3,
Kv1.1, Kv1.2, and KCa1.1. Ce3 is reported to block human Kv1.3 with Ki of 366 nM (5). AgTx2 is reported to block KCa1.1 with Ki1,000 nM (Table S8). Block of
human Kv1.3 in human embryonic kidney (HEK293) cells showed inhibition with an affinity at equilibrium (Ki) of 4.4  0.5 nM (Table S9).








encoding gene, allowing toxin sequencing, overproduction, and
characterization by standardmethods. The strategy also provides
a new source for biologically active neurotoxins. Though strat-
egies such as depletion on secondary targets can be applied (36),
isolation of moka1 is an example of achieving high target
specificity by driving selection for high affinity (37).
Scaffold-based library design should prove applicable to other
targets and selection criteria, for example, to isolate toxins that
bind to receptors in defined functional states. Despite an ap-
parent diversity of millions of toxins in the complete animal
‘‘venome,’’ nature employs a moderate number of molecular
scaffolds. Moreover, toxins typically contain 20–100 amino
acids, a size well handled by phage display. This suggests that
other scaffolds will also prove amenable to designer toxin
development for research, diagnosis, and therapy.
Materials and Methods
An extended version of Materials andMethods is available in SI Materials and
Methods.
KTX Phage Particle and Library Construction.Genes for KTX and DDD-KTX were
constructed usingEscherichia coli codon bias and cloned into pAS62 phagemid
in frame with phage particle coat protein pIII. The combinatorial library was
built based on 31 -KTx toxin or toxin precursor sequences (Arachnida: Scor-
pionida) that exhibit a high sequence similarity to KTX, irrespective of the
toxins’ reported pharmacological property. The 31 sequences were aligned by
the Cys residues forming disulfide bridges, allowing for insertions/deletions.
This alignment defined three domains (Table S1) corresponding to Androc-
tonus mauretanicus kaliotoxin-1 (KTX, -3.1, GenBank accession no. P24662)
residues Gly1-Pro12 (domain A), Leu15-Gly26 (domain B), and Asn30-Lys38 (do-
main C). In designing the library, N-terminal pyroGlu (Z) residues were sub-
stituted by Gly, and from eight toxins, 1–3 aa on either the N or C terminal were
omitted (Table S1). This yielded 30, 22, and 17 unique sequences for domains
A, B, and C, respectively. The sequences between the domains were modified
to match KTX residues Gln13Cys14 (QC) and Lys27Cys28Met29 (KCM) to allow
ligation of nucleotide duplexes and produce inserts with the ABC pattern.
Complementary nucleotide pairs for each unique domain were synthesized,
phosphorylated, and annealed individually. To achieve and monitor domain
incorporation, 90 separate reactions were performed to ligate the ABC inserts
into pAS62. Each of these reactions contained one domain A duplex, 7 or 8
domain B duplexes, and 17 domain C duplexes with the same total moles of A,
B, and C. Ligation mixtures were transformed into E. coliXL1-Blue. This library
resulted in de novo toxins ranging from 31 to 40 aa residues in length, and
reconstitutes 20 original native toxins. Libraries by this method had 8–58%
in-frame ABC toxin sequences, i.e., bona fide unique -KTx scaffold toxins as
confirmed by sequencing.
Phage Particle Binding, ELISA, and Library Screening. For each binding deter-
mination, three wells in a NUNC-Immuno MaxiSorp 96-well plate (Nalge Nunc
International/Thermo Fisher Scientific) were coated overnight at 4 °C with 1
g of KcsA-1.3 or KcsA channels in 50 L of 100 mM NaHCO3 per well, 1 mM
n-dodecyl--d-maltopyranoside (DDM; pH 9.0). Thereafter at room tempera-
ture, wells were then washed once with 50 mM Tris-HCl, 150 mM NaCl (pH 7.5)
containing 0.1% Tween 20, and 1 mM DDM (TBST), and blocked with 200 L
of 50 mM Tris-HCl, 150 mM NaCl (pH 7.5), and 1 mM DDM (TBS) containing
0.5% BSA before washing once with TBST.
For each well, an equal number of phage particles ranging between
108–1010 were added in 50 L of TBS containing 0.5% BSA and incubated on
a rocking shaker for 2 h. Following five washes with TBST, horseradish per-
oxidase conjugated mouse anti-M13 monoclonal antibody (GE Healthcare)
diluted at 1:2,500 in 50 L final volume of TBST with 0.5% BSA was added.
Following incubation on a rocking shaker for 2 h, samples were washed five
times with TBST and twice with TBS. Thereafter, 50 L of 1-Step Turbo
(3,3,5,5 tetramethylbenzidine) TMB-ELISA (Pierce Biotechnology) was added
and the reaction stopped with 50 L 2 M H2SO4. Absorbance was read at 450
nm. Data are mean  SE for three wells.
In selections, wells were prepared, and phage particles added and incu-
bated as above. Poorly adherent phage particles were removed by washing
3–20 times with 200 L TBST. Bound phage particles were eluted with 100 L
of 0.1 M triethylamine by incubation for 10 min on a rocking shaker. The pH
of the eluate was adjusted to between 7.0 and 8.5 with 1 M Tris-HCl (pH 8.0)
before centrifugation at 12,000  g for 5 min. The supernatant was used to
infect E. coli XL1-Blue for reamplification of the library, determination of the
recovery rate, and/or phage particle genotyping. The isolation of two or more
identical clones in a sample of 20 was the basis for further study of a clone, as
the probability of this occurring in the absence of enrichment (e.g., randomly)
is less than 108. Furthermore, with a 50-fold enrichment per cycle, the
probability of observing any one toxin sequence two or more times in a sample
of 20 after two cycles is 0.954; conversely, the probability of observing that
same toxin only once (and therefore our failure to study it further) is just 0.046.
Phage particles were quantified by titering before and after selective library
sorting and genotyped by DNA sequencing (Table S3–S6).
Fig. 4. Moka1 inhibits secretion of effector cytokines by T cells and does not
alter ileal motility and peristaltism. (A) Treatment with moka1 inhibits the
secretion of effector cytokines by T cells. Human CD3 T cells were purified
from peripheral blood of healthy donors and 105 were treated with various
doses of moka1 or KTX starting 1 h before stimulation for 16 h with anti-CD3/
CD28 beads at a 1:1 ratio in triplicate. Supernatants were assessed for TNF-,
IL-2, and IFN- by ELISA. Data represent two independent experiments. Sta-
tistically significant differences between control (no toxin) and test conditions
are indicated (*, P 	 0.05; **,P 	 0.01). Methods are described in-depth in SI
Materials and Methods. (B) Effect of moka1 and KTX on isometric tension
(Upper) and intraluminal pressure (Lower) of guinea pig ileum. Preparations
were exposed to 100 nM moka1 which induced no discernable effect over
15–20 min. Subsequent addition of 10 nM KTX induced twitching and in-
creased peristaltic activity—effects abolished by 1M tetrodotoxin (TTX). Ileal
segments were from adult guinea pigs and studied in modified Krebs-
Henseleit solution at 37 °C. For isometric tension assays, segments were
mounted under tension and responses recorded using a force-displacement
transducer coupled to a polygraph. Toxins were added after 60 min of equil-
ibration (34). For assays of peristalsis, intraluminal perfusion from the oral end
was continuous with pressure recording at the aboral end and the threshold
for contraction used to quantify effects (12). Toxins were added after peri-
staltic activity was stable for 15 min. Methods are described further in SI
Materials and Methods.
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KcsA and KcsA-Kv1.3 Channel Synthesis. The gene for KcsA-Kv1.3 was con-
structed as described by others (27), and the resultant ORF subcloned into
pQE32. XL10 Gold cells (Stratagene) were transformed with cDNA for KcsA or
KcsA-1.3 and grown overnight in LB media with 2% glucose and 200 g/mL
ampicillin. One milliliter of the overnight culture was inoculated into 1 L of LB
media with 200g/mL ampicillin and 0.2% glucose. At OD 600 nm1, protein
expression was induced by addition of 0.5 mM IPTG and 10 mM BaCl2 at 30 °C.
Cells were harvested the next day and lysed by passage through a cell disrupter
in the presence of 50 mM Tris-Cl (pH 7.0), 150 mM KCl (buffer A), and proteases
inhibitors. Centrifugation at 100,000  g yielded a membrane preparation
that was solubilized by addition of 10 mM DDM and incubation for 2 h at 4 °C.
After clarification by centrifugation at 100,000  g, the supernatant was
loaded on a prepacked cobalt column (Clontech). The column was washed
with 20 mM imidazole and protein eluted in a single step with buffer A
containing 1 mM DDM and 500 mM imidazole. The oligomeric state of KcsA
and KcsA-1.3 was corroborated by filtration over Superdex HR 200 followed by
SDS/PAGE (38).
Toxins.AgTx2 was purchased (Alomone Labs). KTX, DDD-KTX, CTX, and moka1
were synthesized using an optimized t-butoxycarbonyl(Boc) solid-phase pro-
tocol (39). Peptide folding reactions were quenched by acidification and
products purified by reverse-phase HPLC. Fractions with the desired protein
were identified by analytical LC-MS, lyophilized, and stored at 80 °C.
Human T Cell Studies. CD3 T cells were purified from peripheral blood of
healthy donors. For IL-2, IFN-, and TNF- assays, 105 freshly isolated cells were
activated using anti-CD3/CD28 dynabeads in 96-well plates, in triplicate. Tox-
ins were added 1 h prior to stimulation. After 16 h of activation, cells were
counted and supernatants analyzed by ELISA.
Guinea Pig Ileum Studies. Ileal segments from adult guinea pigs were studied
in modified Krebs-Henseleit solution at 37 °C. For isometric tension assays,
segments were mounted under tension and responses recorded using a
force-displacement transducer coupled to a polygraph. Toxins were added
after 60 min of equilibration (34). For assays of peristalsis, intraluminal per-
fusion from the oral end was continuous with pressure recording at the aboral
end using the threshold for contraction to quantify effects (12). Toxins were
added after peristaltic activity was stable for 15 min.
Electrophysiology. For two-electrode voltage clamp, Xenopus oocytes were
injected with cDNA encoding rat Kv1.1 (NM173095), rat Kv1.2 (NM012970),
human Kv1.3 (NM002232), and mouse KCa1.1 (NM010610) subcloned into a
dual-use laboratory vector (pMAX or pRAT) with 5 and 3 Xenopus laevis
-globin, a cytomegalovirus promoter for expression in mammalian cells, and
a T7-promoter for in vitro transcription (40). Recording solution was (in mM):
2 KCl, 96 NaCl, 1 MgCl2, 1.8 CaCl2, 5 Hepes (pH 7.5), and 0.1% BSA. Equilibrium
inhibition for moka1 was determined by fitting dose-response curves. Equi-
librium inhibition constants for other toxins were calculated from the per-
centage of block achieved by 1–3 different toxin concentrations that inhibited
between 20% and 80% of currents. kon and koff were calculated (21, 41).
NMR Spectroscopy. [U-13C, 15N]-moka1 was produced in E. coli, purified, and
dissolved in 10 mM sodium phosphate buffer (pH 6.0) in 93% H2O/7% D2O.
NMR spectra were collected on Varian INOVA spectrometer at the 1H fre-
quency of 600 or 500 MHz. Sequence-specific resonance assignments and
structural restraints (distances, dihedral angles, and hydrogen bonds) were
obtained from double- and triple-resonance spectra (42). NMR data were
processed using the NMRPipe suite (43) and analyzed using NMRView (44).
Backbone dihedral angle restraints were obtained from secondary chemical
shift analysis using TALOS (45). Hydrogen bonding restraints were obtained
using long-range HNCO (46). Structure calculation was performed using CY-
ANA with automatic NOE assignment through the CANDID algorithm (47).
Statistics of the final structures are in Table S7.
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